122 176

Cited 4 times in

Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: an open-label randomized controlled trial.

Authors
 Kyoung Heo  ;  Joong Koo Kang  ;  Chang Min Choi  ;  Moo Song Lee  ;  Kyoung Woo Noh  ;  Soon Bae Kim 
Citation
 JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.29(3) : 416-422, 2014 
Journal Title
 JOURNAL OF KOREAN MEDICAL SCIENCE 
ISSN
 1011-8934 
Issue Date
2014
MeSH
Acute Disease ; Adult ; Altitude Sickness/diagnosis ; Altitude Sickness/epidemiology ; Altitude Sickness/prevention & control* ; Blood Pressure/physiology ; Drug Administration Schedule ; Epoetin Alfa ; Erythropoietin/therapeutic use* ; Female ; Headache/physiopathology ; Hemoglobins/analysis ; Humans ; Incidence ; Logistic Models ; Male ; Middle Aged ; Odds Ratio ; Oxygen/blood ; Recombinant Proteins/therapeutic use ; Surveys and Questionnaires
Keywords
Acute Mountain Sickness ; Arterial Oxygen Saturation ; Erythropoietin ; Hemoglobins
Abstract
This study was performed to evaluate whether increasing hemoglobin before ascent by prophylactic erythropoietin injections prevents acute mountain sickness (AMS). This open-label, randomized, controlled trial involved 39 healthy volunteers with hemoglobin ≤15.5 g/dL who were divided randomly into erythropoietin (n=20) and control (n=19) groups. Epoetin alpha 10,000 IU injections were given weekly for four consecutive weeks. On day 1, and 7 days after the last injection (day 29), oxygen saturation (SaO2), and hemoglobin were measured. The subjects departed Seoul on day 30 and arrived at Annapurna base camp (ABC, 4,130 m) on day 34. AMS was diagnosed when headache and Lake Louise score (LLS) of ≥3 were present. Immediate descent criteria followed US Army recommendations. Two groups differ in hemoglobin levels on day 29 (15.4±1.1 vs 14.2±1.0 g/dL, P=0.001). At ABC, erythropoietin group had a significantly lower mean LLS, AMS incidence, and number of subjects who met immediate descent criteria. Multiple logistic regression analysis showed that SaO2<87% and control group, but not hemoglobin<15.0 g/dL, independently predicted satisfaction of immediate descent criteria. Erythropoietin-related adverse effects were not observed. In conclusion, erythropoietin may be an effective prophylaxis for AMS.(Clinical Trial Registry Number; NCT 01665781).
Files in This Item:
T201401155.pdf Download
DOI
10.3346/jkms.2014.29.3.416
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
Yonsei Authors
Heo, Kyoung(허경)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/98620
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse